Product Details
| Product Name:
Evolocumab |
CAS No.:
1256937-27-5 |
| Purity:
95.00% |
Supply Ability:
10g |
| Release date:
2026/05/21 |
Product Introduction
Bioactivity
| Name | Evolocumab |
| Description | Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease. |
| In vitro | METHODS: HUVECs were seeded in 96-well plates at a rate of 1 × 10*5 cells/well in logarithmic growth phase and treated with evolocumab in the concentration range of 0.5-100 mg/ml or vitamin C (Vit C; 50 and 100 mg /ml), then add new medium, expose HUVECs to 0.5 mM H2O2 for 2 hours, and detect HUVECs cell viability by MTT method.
RESULTS Evolocumab significantly inhibited H2O2-induced cytotoxicity at concentrations of 5-100 mg/ml. [2]
METHODS: Rat retinal Müller cells (RMCs) were used as the research object and treated with Evolocumab (100 μg/ml) to study the expression of inflammatory factors in RMCs.
RESULTS Evolocumab treatment (100 μg/ml) reduced the expression and secretion of inflammatory factors in stimulated RMCs (P<0.05), downregulated toll-like receptor-4 (TLR-4) levels in RMCs and inhibited nuclear transcription factor-κB ( NF-κB) phosphorylation (P < 0.05).[4] |
| In vivo | METHODS: In a randomized placebo-controlled clinical study, evolocumab was administered at a dose of 140 mg/2 weeks (Q2W) or 420 mg once a month (QM) for 12 weeks, and LDL-C levels in the body were observed compared with placebo.
RESULTS On average, LDL-C was reduced by approximately 55%-75% at weeks 10 and 12 compared to placebo. [1] |
| Storage | Store at low temperature
-20°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Threonine proteases | Serine proteases | Serine endopeptidases | Ser/Thr Protease | Repatha | PCSK9 | LDLR | Inhibitor | inhibit | hypercholesterolemia | Evolocumab | atherosclerotic cardiovascular disease | AMG-145 | AMG145 | AMG 145 |
| Inhibitors Related | Sodium propionate | Kojic acid | Uridine | Hydroxychloroquine | Fumaric acid | Imidazole | 1,4-Naphthoquinone | Ethyl linoleate | D-Psicose | Proteinase K | N,N-Dimethylacetamide | Ac-Ala-OH |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States